Three questions looming on my mind - welcome any feedback as patience is waning thin. 1. heavy sales investments with personnel in the last 6 months: are there meaningful pipeline deals other than the glacial VA deal? Don't new hires have a Rolodex? 2. Exec team continued selling a wide TAM narrative of clinical, partners, commercial: why persist to hedge after two years and hasn't any one segment proven itself to win at the cost of others or are they chasing their tail? 3. still no product market fit: replicable & predictable sales are still opaque along with any testimonials and client endorsements? very sketch - why?
TTB - General Discussion, page-658
-
- There are more pages in this discussion • 229 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)